(Q50573839)

15 March 2018

title

Evaluation of a pharmacist-managed hepatitis C care clinic. (English)

1 reference

15 March 2018

3

Jonathan D Kaunitz

1 reference

15 March 2018

author name string

Jason P Smith

series ordinal

1

1 reference

15 March 2018

Mamie H Dong

series ordinal

2

1 reference

15 March 2018

publication date

1 March 2007

1 reference

15 March 2018

American Journal of Health-System Pharmacy

published in

1 reference

15 March 2018

volume

64

1 reference

15 March 2018

issue

6

1 reference

15 March 2018

page(s)

632-636

1 reference

15 March 2018

Elevated prevalence of hepatitis C infection in users of United States veterans medical centers

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Therapy of hepatitis C: from empiricism to eradication

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Clinical management of urinary tract infection in women: a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Hepatitis C virus infection in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Side effects of therapy for chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Spectrum of disease in U.S. veteran patients with hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Therapeutic modalities in hepatitis C: challenges and development

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

Limited success of HCV antiviral therapy in United States veterans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

The role of physician extenders in managing patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060153

31 March 2020

Identifiers

DOI

10.2146/AJHP060153

1 reference

15 March 2018

1 reference

15 March 2018